Company Encyclopedia
View More
name
Danaher
DHR.US
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands.
770.89 B
DHR.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking15/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.84%C
    • Profit Margin14.43%B
    • Gross Margin58.20%B
  • Growth ScoreC
    • Revenue YoY2.22%C
    • Net Profit YoY-9.99%D
    • Total Assets YoY-0.89%D
    • Net Assets YoY-0.44%D
  • Cash ScoreC
    • Cash Flow Margin692.78%C
    • OCF YoY2.22%C
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreB
    • Gearing Ratio36.07%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Danaher stock gets a Relative Strength Rating upgrade due to improving price performance, according to IBD.

    Danaher's performance has been on an upward trend, leading to an upgrade in its IBD Relative Strength Rating. The stock has shown significant improvement, reflecting positive numbers and earning recognition in the investment community. This upgrade signifies a positive outlook for Danaher as it continues to demonstrate strong performance in the market.

    Unusual Whales·
    US
    DHR
    -0.58%
    Unusual Whales·
    US
    DHR
    -0.58%

    6 Dividend Stocks Ready To Benefit From 2026’s Rate-Shift Economy

    The article highlights six dividend stocks set to benefit from economic shifts in 2026, driven by expected interest rate cuts and advancements in AI. Annaly Capital and Dynex Capital are positioned to gain from falling mortgage rates, while BlackRock Health Sciences Term Trust and Danaher are poised to profit from accelerated drug development cycles due to AI. The focus is on strategic early investments to capitalize on these trends.

    Forbes·
    US
    DHR
    -0.58%
    US
    DX
    -0.07%
    Forbes·
    US
    DHR
    -0.58%
    US
    DX
    -0.07%

    Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks

    Morgan Stanley analyst Kallum Titchmarsh is optimistic about the life sciences industry, particularly core tools essential for research. He highlights Danaher (DHR) as a top pick, noting its strong financial performance and strategic positioning in biotech and diagnostics. Titchmarsh expects robust pharma R&D budgets and sees bright prospects for core tool providers entering 2026, supported by recent developments and customer demand.

    Tip Ranks·
    US
    DHR
    -0.58%
    Tip Ranks·
    US
    DHR
    -0.58%

    The Bull Case For Danaher (DHR) Could Change Following New Fiduciary-Duty Probe Into Its Boardroom

    Halper Sadeh LLC has launched an investigation into whether Danaher Corporation's officers and directors breached their fiduciary duties to shareholders. This scrutiny could lead to governance reforms and affect Danaher's investment narrative. Despite this, the company's near-term demand outlook remains unchanged. Danaher's projected revenue is $29.2 billion and earnings $5.7 billion by 2028, with a fair value estimate of $254.20, a 12% upside to its current price.

    Simplywall·
    US
    DHR
    -0.58%
    Simplywall·
    US
    DHR
    -0.58%

    Danaher Corporation $DHR Shares Sold by Granite Investment Partners LLC

    Granite Investment Partners LLC reduced its stake in Danaher Corporation by 20.6% in Q2, selling 7,478 shares. The firm's holdings were valued at $5.68 million. Other institutional investors also adjusted their positions in Danaher. Insiders sold 30,248 shares worth $6.61 million last quarter. Analysts have mixed ratings on Danaher, with a consensus "Moderate Buy" and an average price target of $245.75. Danaher's stock opened at $224.21, with a market cap of $158.37 billion.

    Market Beat·
    US
    DHR
    -0.58%
    Market Beat·
    US
    DHR
    -0.58%
    Posts
    View More

    $Danaher(DHR.US) a rung of the ladder from the trade shares sold for excellent profit / $ per share on this group of common shares. I still own some trade shares and have let it rides on the name as ...

    $Danaher(DHR.US) updated chart put more into let it ride 234-235 area has my eye next level

    Source: Sunrise Trader

    • 0

    $Danaher(DHR.US) putting more shares into let it ride.

    Source: Sunrise Trader

    $Danaher(DHR.US) daily updated chart. I did place the first group of shares into let it ride today and if price wants more I will add to let it rides from the trade shares. I did adjust a few stops ...

    • 0

    I still own $Danaher(DHR.US) only long trade I still have. I also own a variety of let it rides but many partials of a variety of names sold today for good to excellent profits.

    Source: Sunrise Trader...

    © 2025 Longbridge｜Disclaimer